Dosing Guidlines for Adults
Drug Detail for Adult Drugs
Teniposide
Miscellaneous Agents
Antineoplastic Agents
- General Toxicity Notes
- Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
- Excreted Unchanged %
- 4-14
- Half-Life (NormalESRD) hours
- 6-10/No data
- Plasma Protein Binding %
- 99
- Volume of Distribution L/kg
- 0.2-0.7
- Dose for Normal Renal Function
- 50-250 mg/m2
- Second Dose
-
- Adjustment for Renal Failure Method
- D
- Adjustment for Renal Failure GFR, mL/min >50 [Recommended Level]
- 100% [D]
- Adjustment for Renal Failure GFR, mL/min 10-50 [Recommended Level]
- 100% [D]
- Adjustment for Renal Failure GFR, mL/min <10 [Recommended Level]
- 100% [D]
- Supplement for Dialysis [Recommendation Level]: IHD
- IHD: None, [D]
- Supplement for Dialysis [Recommendation Level]: PD
- PD: None, [D]
- Supplement for Dialysis [Recommendation Level]: CRRT
- CRRT: No data
- References
- Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet. 1987; 12: 223-52. [PMID: 3297462] / Sinkule JA. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology,pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmaco-therapy. 1984; 4: 61-73. [PMID: 6326063]
- Toxicity Notes
-